English | Spanish
ecancer
Supporting oncology professionals through education
Login Register

The content on this site is intended for healthcare professionals only

  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

News

  • Latest news
  • Sign up for news alerts
  • Submit your news

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Journal information

  • Journal home
  • Charges
  • Editorial board
  • Founding editors
  • Editor-in-chief
  • Contact us

Author information

  • Submit article
  • Author guidelines
  • Editorial policies
  • Copyright information
  • Why publish with us

Reviewer information

  • Reviewer guidelines

Memberships

Open Access Scholarly Publishers Association Crossref Healthcare Information For All Commitee On Publication Ethics

Videos

  • Recent videos
  • Sign up

Explore

  • Bone
  • Brain & nervous system
  • Breast
  • Colorectal & gastro
  • Haematology oncology
  • Head & neck
  • Hepatobiliary pancreatic
  • Lung & pleura
  • Melanoma & skin
  • Neuroendocrine
  • Ovary & gynaecology
  • Paediatric
  • Prostate & urology
  • Sarcomas

Conferences

  • Latest conferences
  • Sign up for latest coverage
  • Submit your event

About ecancer

  • About ecancer
  • Our founders
  • Funding statement
  • Contact us
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Events
  • Conferences
  • About us
Breast Prostate & urology Lung & pleura Colorectal & gastro Melanoma & skin Head & neck Ovary & gynaecology
+ -
Bone Brain & nervous system Haematology oncology Hepatobiliary pancreatic Paediatric Neuroendocrine Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [658]
News [1456]
Articles [246]
Editorials [9]
Conferences [82]
elearning [17]
Five factors identify subset of patients with advanced cervical cancer who may not benefit from bevacizumab treatment
Five factors identify subset of patients with advanced cervical cancer who may not benefit from bevacizumab...
Probing the mystery of how cancer cells die
Probing the mystery of how cancer cells die
Largest ever ovarian cancer trial suggests that screening reduces mortality, but longer follow-up is needed
Largest ever ovarian cancer trial suggests that screening reduces mortality, but longer follow-up is needed
Study suggests that annual CA125 screening may reduce ovarian cancer deaths
Study suggests that annual CA125 screening may reduce ovarian cancer deaths
Research reveals promising novel strategy to target cancer-causing protein
Research reveals promising novel strategy to target cancer-causing protein
Newer cancer drug may help protect kidneys from damage caused by older drug
Newer cancer drug may help protect kidneys from damage caused by older drug
Continuous joint use of oestrogen and progestin lowers risk of EC in postmenopausal women
Continuous joint use of oestrogen and progestin lowers risk of EC in postmenopausal women
Fallopian tube organoids promise better understanding of ovarian cancer and infertility
Fallopian tube organoids promise better understanding of ovarian cancer and infertility
Cancer rates decline in many high-income countries, but rise in lower-income countries
Cancer rates decline in many high-income countries, but rise in lower-income countries
NICE give go ahead for olaparib and enzalutamide, but not abiraterone
NICE give go ahead for olaparib and enzalutamide, but not abiraterone
<1...111112113114115...146>

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Desktop Site
  • Privacy Policy
© 2025 ecancer, all rights reserved
UK registered charity number: 1176307
Back to Top